Mizoribine: an Effective and Low-Toxic Immunosuppressant for Renal Transplantation Patients

陈劲松,季曙明,沙国柱,程震,孙启全,文吉秋,程东瑞,刘志红,黎磊石
DOI: https://doi.org/10.3969/j.issn.1008-8199.2009.01.015
2009-01-01
Abstract:Objective: To investigate the effect and safety of Mizoribine(MZR) in allograft kidney transplantation. Methods: Thirty-eight recipients of first allograft kidney transplantation received Pred+CsA or FK506+MZR while the other 31 Pred+CsA or FK506 + MMF.Comparisons were made between the two groups in the patient/kidney survival rate,SCr,incidence of acute rejection,drug toxicity/side effects(leucopenia,GPT above normal,hyperuricemia and gastrointestinal symptom) and pulmonary infection.Results: No significant differences were observed in the patient/kidney survival rate,acute rejection incidence and SCr between the two groups 1,2 and 3 months after the transplantation.Compared with the MMF group,SCr was significantly increased at 6 and 12 months(P0.05),while the incidences of gastrointestinal symptoms and pulmonary infection markedly decreased in the MZR group(P0.05).No statistic differences were shown in the incidences of leucopenia,GPT above normal and hyperuricemia between the two groups. Conclusion: MZR,with its high safety and low toxicity/side effects,can be used as a maintenance immunosuppressant after allograft kidney transplantation.
What problem does this paper attempt to address?